公开(公告)号：US20190183914A1

公开(公告)日：2019-06-20

申请号：US16246084

申请日：2019-01-11

Applicant: THERAPIX BIOSCIENCES LTD.

Inventor： Ephraim Brener ,  Elran Haber ,  Adi Zuloff-Shani ,  Ascher Shmulewitz

IPC: A61K31/7036 ,  A61K31/43 ,  A61K31/353 ,  A61K31/065 ,  A61K31/16 ,  A61P31/04

CPC classification number: A61K31/7036 ,  A61K31/065 ,  A61K31/16 ,  A61K31/352 ,  A61K31/353 ,  A61K31/43 ,  A61K31/546 ,  A61P31/04 ,  Y02A50/473 ,  A61K2300/00

Abstract: Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.

公开(公告)号：US20160017025A1

公开(公告)日：2016-01-21

申请号：US14774974

申请日：2014-03-13

Applicant: RAMOT AT TEL AVIV UNIVERSITY LTD. ,  THERAPIX BIOSCIENCES LTD.

Inventor： Sarit SAMIRA ,  Nurit RACHAMIM ,  Michael TAL ,  Ronald ELLIS ,  Idan RAKOVER ,  Rom E. ELIAZ ,  Beka SOLOMON ,  Timothy David JONES ,  Francis Joseph CARR ,  Polina RABINOVICH-TOIDMAN ,  Meital SOOLIMAN

IPC: C07K16/18

CPC classification number: C07K16/18 ,  A61K38/00 ,  A61K2039/505 ,  A61K2039/54 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/34 ,  C07K2317/41 ,  C07K2317/54 ,  C07K2317/622 ,  C07K2317/71 ,  C07K2317/76 ,  C07K2317/92

Abstract: Novel antibodies, methods and compositions for treatment of a disease which is susceptible to amelioration by the blocking of APP cleavage.

Abstract translation: 用于治疗易于通过阻断APP切割而改善的疾病的新型抗体，方法和组合物。

公开(公告)号：US20180116982A1

公开(公告)日：2018-05-03

申请号：US15575655

申请日：2016-05-17

Applicant: THERAPIX BIOSCIENCES LTD.

Inventor： Ascher SHMULEWITZ ,  Elran HABER ,  Ephraim BRENER

IPC: A61K31/164 ,  A61K31/485 ,  A61P25/04

CPC classification number: A61K31/164 ,  A61K31/485 ,  A61P25/04 ,  A61K2300/00

Abstract: The present invention provides pharmaceutical compositions comprising opioids and N-acylethanolamines, and methods for their use in preventing and treating a variety of opioid-responsive conditions and opioid-related side-effects.

公开(公告)号：US20150175699A1

公开(公告)日：2015-06-25

申请号：US14408128

申请日：2013-03-12

Applicant: Therapix Biosciences Ltd.

Inventor： Ronald Ellis ,  Michael Tal ,  Sarit Samira ,  Nurit Rachamim ,  Timothy David Jones ,  Francis Joseph Carr ,  Shahar Dotan

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/624

Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.

Abstract translation: 公开了赋予改善的免疫刺激和稳定性的分化3群（CD3）的人源化单克隆抗体（mAb）或其片段。 还公开了包含所述mAb的药物组合物，以及通过与CD3结合而易于改善的治疗方法和任选地还可预防疾病和病症，例如自身免疫疾病，感染性疾病和移植排斥反应。

公开(公告)号：US20220000833A1

公开(公告)日：2022-01-06

申请号：US16965548

申请日：2019-01-25

Applicant: THERAPIX BIOSCIENCES LTD.

Inventor： Adi ZULOFF-SHANI ,  Ephraim BRENER ,  Sscher SHMULEWITZ

IPC: A61K31/352 ,  A61K31/164 ,  A61P21/00 ,  A61P11/00

Abstract: The present disclosure provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines for treating obstructive sleep apnea (OSA). Also disclosed are methods and kits for treating the disease and minimizing OSA symptoms.

公开(公告)号：US20210093652A1

公开(公告)日：2021-04-01

申请号：US16896701

申请日：2020-06-09

Applicant: THERAPIX BIOSCIENCES LTD.

Inventor： Ephraim Brener ,  Elran Haber ,  Adi Zuloff-Shani ,  Ascher Shmulewitz

IPC: A61K31/7036 ,  A61K31/16 ,  A61K31/43 ,  A61K31/352 ,  A61K31/546 ,  A61P31/04 ,  A61K31/065 ,  A61K31/353

Abstract: Disclosed herein are pharmaceutical compositions comprising at least one anti-bacterial and at least one cannabinoid and methods of use in treating or preventing bacterial infection or biofilm in a subject in need thereof.

公开(公告)号：US20200038367A1

公开(公告)日：2020-02-06

申请号：US16598029

申请日：2019-10-10

Applicant: THERAPIX BIOSCIENCES, LTD.

Inventor： Ephraim Brener ,  Elran Haber ,  Ascher Shmulewitz

IPC: A61K31/352 ,  A61K45/06 ,  A61P25/30 ,  A61P25/14 ,  A61P25/00 ,  A61P29/00 ,  A61K31/164 ,  A61K36/185

Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

公开(公告)号：US20200030281A1

公开(公告)日：2020-01-30

申请号：US16589611

申请日：2019-10-01

Applicant: THERAPIX BIOSCIENCES, LTD.

Inventor： Ephraim Brener ,  Elran Haber ,  Ascher Shmulewitz

IPC: A61K31/352 ,  A61K45/06 ,  A61P25/30 ,  A61P25/14 ,  A61P25/00 ,  A61P29/00 ,  A61K31/164 ,  A61K36/185

Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

公开(公告)号：US20200022946A1

公开(公告)日：2020-01-23

申请号：US16557379

申请日：2019-08-30

Applicant: THERAPIX BIOSCIENCES, LTD.

Inventor： Ephraim Brener ,  Elran Haber ,  Ascher Shmulewitz

IPC: A61K31/352 ,  A61K36/185 ,  A61K31/164 ,  A61P29/00 ,  A61P25/00 ,  A61P25/14 ,  A61P25/30 ,  A61K45/06

Abstract: The present invention provides pharmaceutical compositions comprising cannabinoids and N-acylethanolamines, and methods for their use in preventing and treating a variety of cannabinoid-treatable conditions.

公开(公告)号：US20180244778A1

公开(公告)日：2018-08-30

申请号：US15979197

申请日：2018-05-14

Applicant: Therapix Biosciences Ltd.

Inventor： Ronald Ellis ,  Michael Tal ,  Sarit Samira ,  Nurit Rachamim ,  Timothy David Jones ,  Francis Joseph Carr ,  Shahar Dotan

IPC: C07K16/28

CPC classification number: C07K16/2809 ,  A61K2039/505 ,  C07K2317/24 ,  C07K2317/31 ,  C07K2317/56 ,  C07K2317/565 ,  C07K2317/567 ,  C07K2317/622 ,  C07K2317/624

Abstract: Humanized monoclonal antibodies (mAbs) or fragments thereof, to human Cluster of Differentiation 3 (CD3), which confer improved immune stimulation and stability, are disclosed. Pharmaceutical compositions comprising said mAbs and methods of treatment and optionally also prevention of diseases and disorders, such as autoimmune disorders, infectious diseases, and transplant rejection, that are susceptible to amelioration by binding to CD3, are also disclosed.